Ebstein’s Anomaly, Possible Newly Implicated Drug Aetiology? A Case Report
DOI:
https://doi.org/10.17140/HROJ-8-158Keywords:
Ebstein's anomaly, Atrial septal defect (ASD), Nonsteroidal anti-inflammatory drugs (NSAIDs)Abstract
Ebstein’s anomaly is a congenital malformation of the heart that is characterized by downward displacement of an abnormal tricuspid
valve into the right ventricle. It is rare, with an incidence of 1 in 200,000 live births. Etiology is unknown. Our patient was
exposed to artemether-lumefantrine, ciprofloxacin, and ibuprofen (not previously linked with Ebstein’s anomaly) at about four
weeks of gestation. An obstetric scan at 33 weeks’ gestation, was the first clue to the diagnosis.
References
Celermajer DS, Bull C, Till JA, Cullen S, Vassillikos VP, Sullivan ID, et al. Ebstein’s anomaly: Presentation and outcome from fetus to adult. J Am Coll Cardiol. 1994; 23(1): 170-176. doi: 10.1016/0735- 1097(94)90516-9 Submit your article to this journal | https://openventio.org/submit-manuscript/ Case Report | Volume 8 | Number 1| PUBLISHERS
Animasahun BA, Madise-Wobo AD, Kusimo OY. Cyanotic congenital heart diseases among Nigerian children. Cardiovasc Diagn Ther. 2017; 7(4): 389-396. doi: 10.21037/cdt.2017.06.03
Lynch TA, Abel DE. Teratogens and congenital heart disease. J Diagnostic Med Sonogr. 2015; 31(5): 301-305. doi: 10.1177/8756479315598524
Hipona FA, Arthachinta S. Ebstein’s anomaly of the tricuspid valve: A report of 16 cases and review of the literature. Prog Cardiovasc Dis. 1965; 7(5): 434-448. doi: 10.1016/S0033-0620(65)80037-8
Mosha D, Mazuguni F, Mrema S, Sevene E, Abdulla S, Genton B. Safety of artemether-lumefantrine exposure in first trimester of pregnancy: An observational cohort. Malar J. 2014; 13(1): 197. doi: 10.1186/1475-2875-13-197
Schiebler GL, Adams P, Anderson RC, Amplatz K, Lester RG. Clinical study of twenty-three cases of Ebstein’s anomaly of the tricuspid valve. Circulation. 1959; 29: 165-187. doi: 10.1161/01. cir.19.2.165
Shi QY, Zhang JB, Mi YQ, Song Y, Ma J, Zhang YL. congenital heart defects and maternal fever: Systemic review and meta-analysis. J Perinatol. 2014; 34: 677-682. doi: 10.1038/jp.2014.76
Larsen H, Nielsen GL, Schønheyder HC, Olesen C, Sørensen HT. Birth outcome following maternal use of fluoroquinolones. Int J Antimicrob Agents. 2001; 18(3): 259-262. doi: 10.1016/S0924- 8579(01)00390-9
Nakhai-Pour HR, Bérard A. Major malformations after first trimester exposure to aspirin and NSAIDs. Expert Rev Clin Pharmacol. 2008; 1(5): 605-616. doi: 10.1586/17512433.1.5.605
Ye Z, Wang L, Yang T, Chen L, Wang T, Chen L, et al. Maternal viral infection and risk of fetal congenital heart diseases: A meta-analysis of observational studies. J Am Heart Assoc. 2019; 8(9): e011264. doi: 10.1161/JAHA.118.011264
Boston U, Bayle K-M, Kum ar TS, Knott-Craig C. Neonatal ebstein’s anomaly. In: Congenital Anomalies-From the Embryo to the Neonate. NY, USA: In Tech; 2018: doi: 10.5772/intechopen.72891 Animasahun BA et al 20
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Heart Research (HROJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.